Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
By F. Hodi, M. Butler, D. Oble, M. V. Seiden, F. Haluska, A. Kruse, Suzanne Macrae, Marybeth Nelson, C. Canning, I. Lowy and 10 more. Proceedings of the National Academy of Sciences of the United States of America, 2008
675 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b5a7f93d4f15ebd531823f6db46fbc8da22ec1fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- James P. Allison
- G. Freeman
- George Coukos
- Padmanee Sharma
- Shimon Sakaguchi
- M. Miyara
- David A. Hafler
- Jaikumar Duraiswamy
In Oncology
- James P. Allison
- Padmanee Sharma
- G. Freeman
- Shimon Sakaguchi
- George Coukos
- P. Ott
- C. Robert
- A. Korman
Citations in the corpus
- FOXP3+ regulatory T cells in the human immune system (2010, background): “CTLA4-specific blocking monoclonal antibodies (such as ipilimumab (MDX-010; Bristol-Myers Squibb/Medarex), are now in clinical use to treat advanced stages of cance”
- Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “Tumor regression was observed in phase I/II trials in patients with a variety of tumor types, including melanoma, renal cell carcinoma, prostate cancer, urothelial carcinoma, and ovarian cancer (Yang et al., 2007; Hodi et al., 2008; Carthon et al., 2010; van den Eertwegh et al., 2012).”
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells (2013, background): “However, a positive correlation between a high CD8 to Treg ratio and tumor necrosis in biopsies from metastatic melanoma lesions from patients treated with ipilimumab has been described (39).”
- An immune-active tumor microenvironment favors clinical response to ipilimumab (2012, background): “Ipilimumab has been shown to increase tumor-inWltrating lymphocytes [18].”
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013, background): “and CD4 cells, along with tumor necrosis have been clearly identified in biopsies ofmelanomametastases obtained after treatment with ipilimumab (32, 33).”
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, background): “CD4CD25Foxp3 T cells (Tregs) play critical roles in the control of anti-tumor immune responses (21-22, 30-38).”